{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T18:12:01Z","timestamp":1792606321857,"version":"4.5.0"},"reference-count":69,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,11,14]],"date-time":"2025-11-14T00:00:00Z","timestamp":1763078400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,11,14]],"date-time":"2025-11-14T00:00:00Z","timestamp":1763078400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["Intramural research program"],"award-info":[{"award-number":["Intramural research program"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["R01AI162267"],"award-info":[{"award-number":["R01AI162267"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000001","name":"National Science Foundation","doi-asserted-by":"publisher","award":["2400220"],"award-info":[{"award-number":["2400220"]}],"id":[{"id":"10.13039\/100000001","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["npj Vaccines"],"DOI":"10.1038\/s41541-025-01288-6","type":"journal-article","created":{"date-parts":[[2025,11,14]],"date-time":"2025-11-14T06:41:17Z","timestamp":1763102477000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Novel HIV-1 fusion peptide immunogens using glycan-engineered alphavirus-like particles"],"prefix":"10.1038","volume":"10","author":[{"given":"Seo-Ho","family":"Oh","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dedeepya R.","family":"Gudipati","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Shi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peng","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Winston","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey C.","family":"Boyington","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hardik K.","family":"Nariya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emily G.","family":"McGhee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tala","family":"Azzam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vedhika","family":"Raghunathan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chumeng","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catherine","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jane D.","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tongqing","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John R.","family":"Mascola","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lance","family":"Wells","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rui","family":"Kong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,11,14]]},"reference":[{"key":"1288_CR1","doi-asserted-by":"publisher","unstructured":"Haynes, B. F., Burton, D. R. & Mascola, J. R. Multiple roles for HIV broadly neutralizing antibodies. Sci. Transl. Med. 11. https:\/\/doi.org\/10.1126\/scitranslmed.aaz2686 (2019).","DOI":"10.1126\/scitranslmed.aaz2686"},{"key":"1288_CR2","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1038\/s41577-022-00753-w","volume":"23","author":"BF Haynes","year":"2023","unstructured":"Haynes, B. F. et al. Strategies for HIV-1 vaccines that induce broadly neutralizing antibodies. Nat. Rev. Immunol. 23, 142\u2013158 (2023).","journal-title":"Nat. Rev. Immunol."},{"key":"1288_CR3","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.ade4976","volume":"15","author":"SF Andrews","year":"2023","unstructured":"Andrews, S. F. et al. An influenza H1 hemagglutinin stem-only immunogen elicits a broadly cross-reactive B cell response in humans. Sci. Transl. Med 15, eade4976 (2023).","journal-title":"Sci. Transl. Med"},{"key":"1288_CR4","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1016\/j.cell.2018.03.030","volume":"173","author":"YQ Chen","year":"2018","unstructured":"Chen, Y. Q. et al. Influenza infection in humans induces broadly cross-reactive and protective neuraminidase-reactive antibodies. Cell 173, 417\u2013429 e410 (2018).","journal-title":"Cell"},{"key":"1288_CR5","doi-asserted-by":"publisher","first-page":"314","DOI":"10.1038\/s41586-021-04356-8","volume":"602","author":"JJ Guthmiller","year":"2022","unstructured":"Guthmiller, J. J. et al. Broadly neutralizing antibodies target a haemagglutinin anchor epitope. Nature 602, 314\u2013320 (2022).","journal-title":"Nature"},{"key":"1288_CR6","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1016\/j.cell.2016.06.043","volume":"166","author":"MG Joyce","year":"2016","unstructured":"Joyce, M. G. et al. Vaccine-induced antibodies that neutralize Group 1 and Group 2 influenza A viruses. Cell 166, 609\u2013623 (2016).","journal-title":"Cell"},{"key":"1288_CR7","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1038\/s41577-019-0143-6","volume":"19","author":"F Krammer","year":"2019","unstructured":"Krammer, F. The human antibody response to influenza A virus infection and vaccination. Nat. Rev. Immunol. 19, 383\u2013397 (2019).","journal-title":"Nat. Rev. Immunol."},{"key":"1288_CR8","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1126\/science.aay0678","volume":"366","author":"D Stadlbauer","year":"2019","unstructured":"Stadlbauer, D. et al. Broadly protective human antibodies that target the active site of influenza virus neuraminidase. Science 366, 499\u2013504 (2019).","journal-title":"Science"},{"key":"1288_CR9","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.abi9215","volume":"14","author":"P Zhou","year":"2022","unstructured":"Zhou, P. et al. A human antibody reveals a conserved site on beta-coronavirus spike proteins and confers protection against SARS-CoV-2 infection. Sci. Transl. Med. 14, eabi9215 (2022).","journal-title":"Sci. Transl. Med."},{"key":"1288_CR10","doi-asserted-by":"publisher","first-page":"288","DOI":"10.1016\/j.immuni.2018.07.009","volume":"49","author":"M Bianchi","year":"2018","unstructured":"Bianchi, M. et al. Electron-microscopy-based epitope mapping defines specificities of polyclonal antibodies elicited during HIV-1 BG505 envelope trimer immunization. Immunity 49, 288\u2013300 e288 (2018).","journal-title":"Immunity"},{"key":"1288_CR11","doi-asserted-by":"publisher","first-page":"e1008753","DOI":"10.1371\/journal.ppat.1008753","volume":"16","author":"CA Cottrell","year":"2020","unstructured":"Cottrell, C. A. et al. Mapping the immunogenic landscape of near-native HIV-1 envelope trimers in non-human primates. PLoS Pathog. 16, e1008753 (2020).","journal-title":"PLoS Pathog."},{"key":"1288_CR12","doi-asserted-by":"publisher","first-page":"2327","DOI":"10.1016\/j.celrep.2016.07.074","volume":"16","author":"LE McCoy","year":"2016","unstructured":"McCoy, L. E. et al. Holes in the glycan shield of the native HIV envelope are a target of trimer-elicited neutralizing antibodies. Cell Rep. 16, 2327\u20132338 (2016).","journal-title":"Cell Rep."},{"key":"1288_CR13","doi-asserted-by":"publisher","first-page":"3755","DOI":"10.1016\/j.celrep.2020.02.061","volume":"30","author":"B Nogal","year":"2020","unstructured":"Nogal, B. et al. Mapping polyclonal antibody responses in non-human primates vaccinated with HIV Env trimer subunit vaccines. Cell Rep. 30, 3755\u20133765 e3757 (2020).","journal-title":"Cell Rep."},{"key":"1288_CR14","doi-asserted-by":"publisher","DOI":"10.1016\/j.isci.2023.107403","volume":"26","author":"AS Olia","year":"2023","unstructured":"Olia, A. S. et al. Soluble prefusion-closed HIV-envelope trimers with glycan-covered bases. iScience 26, 107403 (2023).","journal-title":"iScience"},{"key":"1288_CR15","doi-asserted-by":"publisher","first-page":"998","DOI":"10.1038\/s41586-022-05216-9","volume":"609","author":"JH Lee","year":"2022","unstructured":"Lee, J. H. et al. Long-primed germinal centres with enduring affinity maturation and clonal migration. Nature 609, 998\u20131004 (2022).","journal-title":"Nature"},{"key":"1288_CR16","doi-asserted-by":"publisher","DOI":"10.1126\/sciimmunol.abf1152","volume":"6","author":"M Silva","year":"2021","unstructured":"Silva, M. et al. A particulate saponin\/TLR agonist vaccine adjuvant alters lymph flow and modulates adaptive immunity. Sci. Immunol. 6, eabf1152 (2021).","journal-title":"Sci. Immunol."},{"key":"1288_CR17","doi-asserted-by":"publisher","first-page":"E6639","DOI":"10.1073\/pnas.1606050113","volume":"113","author":"HH Tam","year":"2016","unstructured":"Tam, H. H. et al. Sustained antigen availability during germinal center initiation enhances antibody responses to vaccination. Proc. Natl Acad. Sci. USA 113, E6639\u2013E6648 (2016).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"1288_CR18","doi-asserted-by":"publisher","unstructured":"Bale, S. et al. Covalent linkage of HIV-1 trimers to synthetic liposomes elicits improved B cell and antibody responses. J. Virol. 91, https:\/\/doi.org\/10.1128\/JVI.00443-17 (2017).","DOI":"10.1128\/JVI.00443-17"},{"key":"1288_CR19","doi-asserted-by":"publisher","first-page":"1188","DOI":"10.1016\/j.cell.2021.01.035","volume":"184","author":"PJM Brouwer","year":"2021","unstructured":"Brouwer, P. J. M. et al. Two-component spike nanoparticle vaccine protects macaques from SARS-CoV-2 infection. Cell 184, 1188\u20131200 e1119 (2021).","journal-title":"Cell"},{"key":"1288_CR20","doi-asserted-by":"publisher","DOI":"10.1126\/sciimmunol.adn0622","volume":"9","author":"X Wang","year":"2024","unstructured":"Wang, X. et al. mRNA-LNP prime boost evolves precursors toward VRC01-like broadly neutralizing antibodies in preclinical humanized mouse models. Sci. Immunol. 9, eadn0622 (2024).","journal-title":"Sci. Immunol."},{"key":"1288_CR21","doi-asserted-by":"publisher","DOI":"10.1126\/science.adk0582","volume":"384","author":"Z Xie","year":"2024","unstructured":"Xie, Z. et al. mRNA-LNP HIV-1 trimer boosters elicit precursors to broad neutralizing antibodies. Science 384, eadk0582 (2024).","journal-title":"Science"},{"key":"1288_CR22","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1038\/s41591-020-1118-7","volume":"27","author":"R Nachbagauer","year":"2021","unstructured":"Nachbagauer, R. et al. A chimeric hemagglutinin-based universal influenza virus vaccine approach induces broad and long-lasting immunity in a randomized, placebo-controlled phase I trial. Nat. Med. 27, 106\u2013114 (2021).","journal-title":"Nat. Med."},{"key":"1288_CR23","doi-asserted-by":"publisher","DOI":"10.1126\/sciadv.adi4753","volume":"9","author":"E Puente-Massaguer","year":"2023","unstructured":"Puente-Massaguer, E. et al. Chimeric hemagglutinin split vaccines elicit broadly cross-reactive antibodies and protection against group 2 influenza viruses in mice. Sci. Adv. 9, eadi4753 (2023).","journal-title":"Sci. Adv."},{"key":"1288_CR24","doi-asserted-by":"publisher","first-page":"398","DOI":"10.1016\/j.immuni.2019.06.024","volume":"51","author":"SF Andrews","year":"2019","unstructured":"Andrews, S. F. et al. Activation dynamics and immunoglobulin evolution of pre-existing and newly generated human memory B cell responses to influenza hemagglutinin. Immunity 51, 398\u2013410 e395 (2019).","journal-title":"Immunity"},{"key":"1288_CR25","doi-asserted-by":"publisher","unstructured":"Andrews, S. F. et al. Preferential induction of cross-group influenza A hemagglutinin stem-specific memory B cells after H7N9 immunization in humans. Sci. Immunol. 2, https:\/\/doi.org\/10.1126\/sciimmunol.aan2676 (2017).","DOI":"10.1126\/sciimmunol.aan2676"},{"key":"1288_CR26","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1016\/j.coi.2018.04.009","volume":"53","author":"SF Andrews","year":"2018","unstructured":"Andrews, S. F. & McDermott, A. B. Shaping a universally broad antibody response to influenza amidst a variable immunoglobulin landscape. Curr. Opin. Immunol. 53, 96\u2013101 (2018).","journal-title":"Curr. Opin. Immunol."},{"key":"1288_CR27","doi-asserted-by":"publisher","unstructured":"Guthmiller, J. J. et al. First exposure to the pandemic H1N1 virus induced broadly neutralizing antibodies targeting hemagglutinin head epitopes. Sci. Transl. Med. 13, https:\/\/doi.org\/10.1126\/scitranslmed.abg4535 (2021).","DOI":"10.1126\/scitranslmed.abg4535"},{"key":"1288_CR28","doi-asserted-by":"publisher","unstructured":"Guthmiller, J. J. et al. Long-lasting B cell convergence to distinct broadly reactive epitopes following vaccination with chimeric influenza virus hemagglutinins. Immunity https:\/\/doi.org\/10.1016\/j.immuni.2025.02.025 (2025).","DOI":"10.1016\/j.immuni.2025.02.025"},{"key":"1288_CR29","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-021-23977-1","volume":"12","author":"T Aydillo","year":"2021","unstructured":"Aydillo, T. et al. Immunological imprinting of the antibody response in COVID-19 patients. Nat. Commun. 12, 3781 (2021).","journal-title":"Nat. Commun."},{"key":"1288_CR30","doi-asserted-by":"publisher","first-page":"950","DOI":"10.1038\/s41586-024-07539-1","volume":"630","author":"CY Liang","year":"2024","unstructured":"Liang, C. Y. et al. Imprinting of serum neutralizing antibodies by Wuhan-1 mRNA vaccines. Nature 630, 950\u2013960 (2024).","journal-title":"Nature"},{"key":"1288_CR31","doi-asserted-by":"publisher","DOI":"10.1016\/j.xcrm.2023.101258","volume":"4","author":"Q Wang","year":"2023","unstructured":"Wang, Q. et al. Deep immunological imprinting due to the ancestral spike in the current bivalent COVID-19 vaccine. Cell Rep. Med. 4, 101258 (2023).","journal-title":"Cell Rep. Med."},{"key":"1288_CR32","doi-asserted-by":"publisher","first-page":"e1012558","DOI":"10.1371\/journal.ppat.1012558","volume":"20","author":"M Brinkkemper","year":"2024","unstructured":"Brinkkemper, M. et al. Mosaic and mixed HIV-1 glycoprotein nanoparticles elicit antibody responses to broadly neutralizing epitopes. PLoS Pathog. 20, e1012558 (2024).","journal-title":"PLoS Pathog."},{"key":"1288_CR33","doi-asserted-by":"publisher","first-page":"915","DOI":"10.1016\/j.immuni.2019.10.008","volume":"51","author":"V Dubrovskaya","year":"2019","unstructured":"Dubrovskaya, V. et al. Vaccination with glycan-modified HIV NFL envelope trimer-liposomes elicits broadly neutralizing antibodies to multiple sites of vulnerability. Immunity 51, 915\u2013929 e917 (2019).","journal-title":"Immunity"},{"key":"1288_CR34","doi-asserted-by":"publisher","unstructured":"Torrents de la Pena, A. et al. Immunogenicity in rabbits of HIV-1 SOSIP trimers from clades A, B, and C, given individually, sequentially, or in combination. J. Virol. 92, https:\/\/doi.org\/10.1128\/JVI.01957-17 (2018).","DOI":"10.1128\/JVI.01957-17"},{"key":"1288_CR35","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-017-01549-6","volume":"8","author":"DW Kulp","year":"2017","unstructured":"Kulp, D. W. et al. Structure-based design of native-like HIV-1 envelope trimers to silence non-neutralizing epitopes and eliminate CD4 binding. Nat. Commun. 8, 1655 (2017).","journal-title":"Nat. Commun."},{"key":"1288_CR36","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2021.108933","volume":"35","author":"R Derking","year":"2021","unstructured":"Derking, R. et al. Enhancing glycan occupancy of soluble HIV-1 envelope trimers to mimic the native viral spike. Cell Rep. 35, 108933 (2021).","journal-title":"Cell Rep."},{"key":"1288_CR37","doi-asserted-by":"publisher","first-page":"828","DOI":"10.1126\/science.aae0474","volume":"352","author":"R Kong","year":"2016","unstructured":"Kong, R. et al. Fusion peptide of HIV-1 as a site of vulnerability to neutralizing antibody. Science 352, 828\u2013833 (2016).","journal-title":"Science"},{"key":"1288_CR38","doi-asserted-by":"publisher","DOI":"10.1038\/nmicrobiol.2016.199","volume":"2","author":"MJ van Gils","year":"2016","unstructured":"van Gils, M. J. et al. An HIV-1 antibody from an elite neutralizer implicates the fusion peptide as a site of vulnerability. Nat. Microbiol. 2, 16199 (2016).","journal-title":"Nat. Microbiol."},{"key":"1288_CR39","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1016\/j.cell.2019.06.030","volume":"178","author":"R Kong","year":"2019","unstructured":"Kong, R. et al. Antibody lineages with vaccine-induced antigen-binding hotspots develop broad HIV neutralization. Cell 178, 567\u2013584 e519 (2019).","journal-title":"Cell"},{"key":"1288_CR40","doi-asserted-by":"publisher","first-page":"857","DOI":"10.1038\/s41591-018-0042-6","volume":"24","author":"K Xu","year":"2018","unstructured":"Xu, K. et al. Epitope-based vaccine design yields fusion peptide-directed antibodies that neutralize diverse strains of HIV-1. Nat. Med 24, 857\u2013867 (2018).","journal-title":"Nat. Med"},{"key":"1288_CR41","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2020.107981","volume":"32","author":"C Cheng","year":"2020","unstructured":"Cheng, C. et al. Immune monitoring reveals fusion peptide priming to imprint cross-clade HIV-neutralizing responses with a characteristic early B cell signature. Cell Rep. 32, 107981 (2020).","journal-title":"Cell Rep."},{"key":"1288_CR42","doi-asserted-by":"publisher","first-page":"e0215163","DOI":"10.1371\/journal.pone.0215163","volume":"14","author":"C Cheng","year":"2019","unstructured":"Cheng, C. et al. Consistent elicitation of cross-clade HIV-neutralizing responses achieved in guinea pigs after fusion peptide priming by repetitive envelope trimer boosting. PLoS ONE 14, e0215163 (2019).","journal-title":"PLoS ONE"},{"key":"1288_CR43","doi-asserted-by":"publisher","unstructured":"Chuang, G. Y. et al. Development of a 3Mut-apex-stabilized envelope trimer that expands HIV-1 neutralization breadth when used to boost fusion peptide-directed vaccine-elicited responses. J. Virol. 94, https:\/\/doi.org\/10.1128\/JVI.00074-20 (2020).","DOI":"10.1128\/JVI.00074-20"},{"key":"1288_CR44","doi-asserted-by":"publisher","unstructured":"Ou, L. et al. Assessment of crosslinkers between peptide antigen and carrier protein for fusion peptide-directed vaccines against HIV-1. Vaccines (Basel) 10, https:\/\/doi.org\/10.3390\/vaccines10111916 (2022).","DOI":"10.3390\/vaccines10111916"},{"key":"1288_CR45","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-020-59711-y","volume":"10","author":"L Ou","year":"2020","unstructured":"Ou, L. et al. Preclinical development of a fusion peptide conjugate as an HIV vaccine immunogen. Sci. Rep. 10, 3032 (2020).","journal-title":"Sci. Rep."},{"key":"1288_CR46","doi-asserted-by":"publisher","DOI":"10.1128\/jvi.01604-22","volume":"97","author":"M Sastry","year":"2023","unstructured":"Sastry, M. et al. Diverse murine vaccinations reveal distinct antibody classes to target fusion peptide and variation in peptide length to improve HIV neutralization. J. Virol. 97, e0160422 (2023).","journal-title":"J. Virol."},{"key":"1288_CR47","doi-asserted-by":"publisher","first-page":"1369","DOI":"10.1001\/jama.2020.2477","volume":"323","author":"GL Chen","year":"2020","unstructured":"Chen, G. L. et al. Effect of a chikungunya virus-like particle vaccine on safety and tolerability outcomes: a randomized clinical trial. JAMA 323, 1369\u20131377 (2020).","journal-title":"JAMA"},{"key":"1288_CR48","doi-asserted-by":"publisher","first-page":"1210","DOI":"10.1016\/S1473-3099(22)00052-4","volume":"22","author":"EE Coates","year":"2022","unstructured":"Coates, E. E. et al. Safety and immunogenicity of a trivalent virus-like particle vaccine against western, eastern, and Venezuelan equine encephalitis viruses: a phase 1, open-label, dose-escalation, randomised clinical trial. Lancet Infect. Dis. 22, 1210\u20131220 (2022).","journal-title":"Lancet Infect. Dis."},{"key":"1288_CR49","doi-asserted-by":"publisher","first-page":"334","DOI":"10.1038\/nm.2105","volume":"16","author":"W Akahata","year":"2010","unstructured":"Akahata, W. et al. A virus-like particle vaccine for epidemic Chikungunya virus protects nonhuman primates against infection. Nat. Med. 16, 334\u2013338 (2010).","journal-title":"Nat. Med."},{"key":"1288_CR50","doi-asserted-by":"publisher","first-page":"2046","DOI":"10.1016\/S0140-6736(14)61185-5","volume":"384","author":"LJ Chang","year":"2014","unstructured":"Chang, L. J. et al. Safety and tolerability of chikungunya virus-like particle vaccine in healthy adults: a phase 1 dose-escalation trial. Lancet 384, 2046\u20132052 (2014).","journal-title":"Lancet"},{"key":"1288_CR51","doi-asserted-by":"publisher","first-page":"8890","DOI":"10.1073\/pnas.1910670117","volume":"117","author":"CL Chen","year":"2020","unstructured":"Chen, C. L. et al. Cryo-EM structure of eastern equine encephalitis virus in complex with heparan sulfate analogues. Proc. Natl Acad. Sci. USA 117, 8890\u20138899 (2020).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"1288_CR52","doi-asserted-by":"publisher","first-page":"737","DOI":"10.1172\/JCI84417","volume":"127","author":"LA Silva","year":"2017","unstructured":"Silva, L. A. & Dermody, T. S. Chikungunya virus: epidemiology, replication, disease mechanisms, and prospective intervention strategies. J. Clin. Invest. 127, 737\u2013749 (2017).","journal-title":"J. Clin. Invest."},{"key":"1288_CR53","doi-asserted-by":"publisher","first-page":"3854","DOI":"10.1038\/emboj.2011.261","volume":"30","author":"R Zhang","year":"2011","unstructured":"Zhang, R. et al. 4.4 A cryo-EM structure of an enveloped alphavirus Venezuelan equine encephalitis virus. EMBO J. 30, 3854\u20133863 (2011).","journal-title":"EMBO J."},{"key":"1288_CR54","doi-asserted-by":"publisher","first-page":"1725","DOI":"10.1016\/j.cell.2019.04.006","volume":"177","author":"K Basore","year":"2019","unstructured":"Basore, K. et al. Cryo-EM structure of chikungunya virus in complex with the Mxra8 receptor. Cell 177, 1725\u20131737 e1716 (2019).","journal-title":"Cell"},{"key":"1288_CR55","doi-asserted-by":"publisher","first-page":"1884","DOI":"10.1016\/j.cell.2020.11.011","volume":"183","author":"LE Williamson","year":"2020","unstructured":"Williamson, L. E. et al. Human antibodies protect against aerosolized eastern equine encephalitis virus infection. Cell 183, 1884\u20131900 e1823 (2020).","journal-title":"Cell"},{"key":"1288_CR56","doi-asserted-by":"publisher","first-page":"2672","DOI":"10.1016\/j.cell.2023.05.019","volume":"186","author":"MS Sutton","year":"2023","unstructured":"Sutton, M. S. et al. Vaccine elicitation and structural basis for antibody protection against alphaviruses. Cell 186, 2672\u20132689 e2625 (2023).","journal-title":"Cell"},{"key":"1288_CR57","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1016\/j.immuni.2018.07.005","volume":"49","author":"H Duan","year":"2018","unstructured":"Duan, H. et al. Glycan masking focuses immune responses to the HIV-1 CD4-binding site and enhances elicitation of VRC01-class precursor antibodies. Immunity 49, 301\u2013311 e305 (2018).","journal-title":"Immunity"},{"key":"1288_CR58","doi-asserted-by":"publisher","first-page":"522","DOI":"10.1038\/nsmb.3051","volume":"22","author":"YD Kwon","year":"2015","unstructured":"Kwon, Y. D. et al. Crystal structure, conformational fixation and entry-related interactions of mature ligand-free HIV-1 Env. Nat. Struct. Mol. Biol. 22, 522\u2013531 (2015).","journal-title":"Nat. Struct. Mol. Biol."},{"key":"1288_CR59","doi-asserted-by":"publisher","first-page":"e1003618","DOI":"10.1371\/journal.ppat.1003618","volume":"9","author":"RW Sanders","year":"2013","unstructured":"Sanders, R. W. et al. A next-generation cleaved, soluble HIV-1 Env trimer, BG505 SOSIP.664 gp140, expresses multiple epitopes for broadly neutralizing but not non-neutralizing antibodies. PLoS Pathog. 9, e1003618 (2013).","journal-title":"PLoS Pathog."},{"key":"1288_CR60","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1016\/j.cell.2023.12.002","volume":"187","author":"KO Saunders","year":"2024","unstructured":"Saunders, K. O. et al. Vaccine induction of CD4-mimicking HIV-1 broadly neutralizing antibody precursors in macaques. Cell 187, 79\u201394 e24 (2024).","journal-title":"Cell"},{"key":"1288_CR61","doi-asserted-by":"publisher","first-page":"101477","DOI":"10.1016\/j.eclinm.2022.101477","volume":"48","author":"KV Houser","year":"2022","unstructured":"Houser, K. V. et al. Safety and immunogenicity of an HIV-1 prefusion-stabilized envelope trimer (Trimer 4571) vaccine in healthy adults: A first-in-human open-label, randomized, dose-escalation, phase 1 clinical trial. EClinicalMedicine 48, 101477 (2022).","journal-title":"EClinicalMedicine"},{"key":"1288_CR62","doi-asserted-by":"publisher","first-page":"e25165","DOI":"10.1371\/journal.pone.0025165","volume":"6","author":"DJ Lewis","year":"2011","unstructured":"Lewis, D. J. et al. Phase I randomised clinical trial of an HIV-1(CN54), clade C, trimeric envelope vaccine candidate delivered vaginally. PLoS ONE 6, e25165 (2011).","journal-title":"PLoS ONE"},{"key":"1288_CR63","doi-asserted-by":"publisher","first-page":"105544","DOI":"10.1016\/j.ebiom.2024.105544","volume":"112","author":"KM Pollock","year":"2025","unstructured":"Pollock, K. M. et al. Experimental medicine study with stabilised native-like HIV-1 Env immunogens drives long-term antibody responses, but lacks neutralising breadth. EBioMedicine 112, 105544 (2025).","journal-title":"EBioMedicine"},{"key":"1288_CR64","doi-asserted-by":"publisher","first-page":"6309","DOI":"10.1016\/j.vaccine.2023.07.046","volume":"41","author":"HV Tieu","year":"2023","unstructured":"Tieu, H. V. et al. Safety and immunogenicity of a recombinant oligomeric gp145 subtype C Env protein (gp145 C.6980) HIV vaccine candidate in healthy, HIV-1-uninfected adult participants in the US. Vaccine 41, 6309\u20136317 (2023).","journal-title":"Vaccine"},{"key":"1288_CR65","doi-asserted-by":"publisher","unstructured":"Romanov, A. et al. DNA origami vaccines program antigen-focused germinal centers. bioRxiv https:\/\/doi.org\/10.1101\/2025.02.21.639354 (2025).","DOI":"10.1101\/2025.02.21.639354"},{"key":"1288_CR66","doi-asserted-by":"publisher","first-page":"716","DOI":"10.1038\/s41565-020-0719-0","volume":"15","author":"R Veneziano","year":"2020","unstructured":"Veneziano, R. et al. Role of nanoscale antigen organization on B-cell activation probed using DNA origami. Nat. Nanotechnol. 15, 716\u2013723 (2020).","journal-title":"Nat. Nanotechnol."},{"key":"1288_CR67","doi-asserted-by":"publisher","first-page":"586","DOI":"10.1016\/j.chom.2020.08.004","volume":"28","author":"P Zhao","year":"2020","unstructured":"Zhao, P. et al. Virus-receptor interactions of glycosylated SARS-CoV-2 spike and human ACE2 receptor. Cell Host Microbe 28, 586\u2013601 e586 (2020).","journal-title":"Cell Host Microbe"},{"key":"1288_CR68","doi-asserted-by":"publisher","first-page":"1515","DOI":"10.1038\/s41592-021-01306-0","volume":"18","author":"WF Zeng","year":"2021","unstructured":"Zeng, W. F., Cao, W. Q., Liu, M. Q., He, S. M. & Yang, P. Y. Precise, fast and comprehensive analysis of intact glycopeptides and modified glycans with pGlyco3. Nat. Methods 18, 1515\u20131523 (2021).","journal-title":"Nat. Methods"},{"key":"1288_CR69","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2024.113948","volume":"43","author":"MK Tenggara","year":"2024","unstructured":"Tenggara, M. K. et al. Frequency-potency analysis of IgG+ memory B cells delineates neutralizing antibody responses at single-cell resolution. Cell Rep. 43, 113948 (2024).","journal-title":"Cell Rep."}],"container-title":["npj Vaccines"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41541-025-01288-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41541-025-01288-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41541-025-01288-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,14]],"date-time":"2025-11-14T18:03:33Z","timestamp":1763143413000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41541-025-01288-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,14]]},"references-count":69,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["1288"],"URL":"https:\/\/doi.org\/10.1038\/s41541-025-01288-6","relation":{},"ISSN":["2059-0105"],"issn-type":[{"value":"2059-0105","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,14]]},"assertion":[{"value":"7 June 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 September 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 November 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A US Provisional Patent Application No. 63\/798,203 covering the glycan-engineered VLPs has been filed by Emory University.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"232"}}